25 results
6-K
EX-99.1
OBSVF
ObsEva SA
14 Aug 20
Current report (foreign)
4:24pm
to menopause* Black woman, weighing 230 lbs Moderate hypertension, not well-controlled Worsening heavy bleeding and pain related to UF The only GnRH … linzagolix ABT Keisha, 42 – Needs a rapid & substantial reduction in uterine volume Black woman with bulky 26-week-sized uterus and MRI suggestive
6-K
EX-99.1
OBSVF
ObsEva SA
7 Jul 20
Current report (foreign)
3:39pm
(5.9) 41.8 (5.9) 42.9 (5.3) 43.4 (5.4) 43.1 (4.8) Proportion of Black women % 63 64 61 5 4 4 BMI (kg/m2)—mean (SD)* 32.2 (6.8) 33.3 (7.4) 33.0 (7.3) 26.8 … trials have been US EU/US US US US/RoW US/RoW completed, nor are underway 200 mg QD + ABT 300 mg BID + ABT 40 mg QD + ABT Black women % 61 4 67 48 BMI
6-K
EX-99.1
OBSVF
ObsEva SA
4 Jan 21
ObsEva appoints David Renas as Chief Financial Officer
6:36am
at Adkins Black LLP. Prior to focusing on the life sciences industry, he was an attorney in private practice with Gray Cary Ware & Freidenrich (now
6-K
EX-99.1
OBSVF
ObsEva SA
13 Jan 21
Current report (foreign)
4:00pm
women suffering from uterine fibroids may have a contraindication to hormonal ABT* Black women are overrepresented 27 0% 10% 20% 30% 40% 50% 60 … % Obesity (BMI ≥ 30) in women aged ≥20 Non-Hispanic Black Non-hispanic White Severe obesity (BMI ≥40) in women aged ≥20 Smokers aged ≥18 Hypertension
6-K
OBSVF
ObsEva SA
15 Jan 20
Current report (foreign)
8:35pm
** (mL) at baseline mean (SD) 218 (128) 246 (161) 193 (92) 219 (136) 212 (142) 218 (134) 95% Caucasian / 5% Black
Primrose 2 Phase 3 – Uterine Fibroids … higher BMD than other races1,2 Unadjusted LS/FN BMDs 7-12% & 14-24% higher in black vs white women6 Caucasian race is a known risk factor for lower BMD
6-K/A
EX-99.1
ps3u77uo
19 Jan 21
Current report (foreign) (amended)
6:25am
6-K
EX-99.1
ykt93c52
17 May 22
Index to Unaudited Condensed Consolidated Financial Statements
7:00am
6-K
EX-99.2
l41ze kbi0
17 Feb 21
ObsEva to Present at the SVB Leerink 10th Annual Global Healthcare Conference
6:04am
6-K
EX-99.2
nw18heym647 vy
1 Jun 21
ObsEva SA Announces that Shareholders Approved all Board Proposals at its
6:30am
6-K
u2avs ghaot4
13 Nov 19
Index to Unaudited Condensed Consolidated Financial Statements
4:00pm
6-K
EX-99.1
pgcpp79gydoz in
31 Mar 21
Current report (foreign)
7:15am
6-K/A
EX-99.1
x8u xkqmty
13 Sep 22
Index to Unaudited Condensed Consolidated Financial Statements
9:08am
6-K
EX-99.1
lglrd
17 Aug 22
Index to Unaudited Condensed Consolidated Financial Statements
4:01pm
6-K
EX-99.1
477xj 9lk25ityy
1 Dec 22
Index to Unaudited Condensed Consolidated Financial Statements
4:15pm
6-K
EX-99.2
t70pb8w
10 Dec 19
ObsEva Announces Positive Results from Uterine Fibroids Phase 3 Study (PRIMROSE 2) of Linzagolix
12:00am
10-K
zdvnzcwm61fp9dw1lzf4
31 Mar 23
Annual report
4:01pm